{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:03:58Z","timestamp":1779764638668,"version":"3.53.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:p>Regular blood monitoring is currently advocated for patients with psoriasis receiving biologic therapy because of their immunomodulatory potential. Our study presents long-term follow-up data from a large cohort of patients with psoriasis and demonstrates a low incidence of discontinuation of biologic therapy as a result of laboratory abnormalities. We discuss the potential implications of the relevant findings for future blood monitoring guidance, particularly given the growing number of patients being treated with biologics.<\/jats:p>","DOI":"10.1093\/ced\/llag058","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:38:30Z","timestamp":1769863110000},"page":"1113-1116","source":"Crossref","is-referenced-by-count":0,"title":["Time to reconsider blood monitoring guidance: a retrospective review of patients with psoriasis requiring discontinuation of biologic therapy"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-9580","authenticated-orcid":false,"given":"Younghoon","family":"Kim","sequence":"first","affiliation":[{"name":"Dermatology Department, Barts Health NHS Trust , London ,","place":["UK"]},{"name":"East Sussex Healthcare NHS Trust , St Leonards-on-Sea ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Yi Liang","family":"Tan","sequence":"additional","affiliation":[{"name":"Dermatology Department, Barts Health NHS Trust , London ,","place":["UK"]},{"name":"Ministry of Heath Holdings ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[{"name":"Dermatology Department, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Mohandas","sequence":"additional","affiliation":[{"name":"Dermatology Department, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mehrtens","sequence":"additional","affiliation":[{"name":"Dermatology Department, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026052522563538500_llag058-B1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026052522563538500_llag058-B2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026052522563538500_llag058-B3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/ced\/llad340","article-title":"Adopting a personalized approach to blood monitoring in patients with psoriasis prescribed biologic therapy: a retrospective single-centre review of real-world data","volume":"49","author":"Hussain","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2026052522563538500_llag058-B4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/bjd\/ljad430","article-title":"Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies","volume":"190","author":"Abhishek","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026052522563538500_llag058-B5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag058\/66716699\/llag058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1113\/66716699\/llag058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1113\/66716699\/llag058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:56:44Z","timestamp":1779764204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/1113\/8455752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":5,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag058","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,3]]}}}